SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)
Clin. transl. oncol. (Print)
; 24(4): 703-711, abril 2022. ilus
Article
in En
| IBECS
| ID: ibc-203774
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Central nervous system (CNS) dissemination is a severe complication in cancer and a leading cause of cancer-related mortality. Brain metastases (BMs) are the most common types of malignant intracranial tumors and are reported in approximately 25% of patients with metastatic cancers. The recent increase in incidence of BMs is due to several factors including better diagnostic assessments and the development of improved systemic therapies that have lower activity on the CNS. However, newer systemic therapies are being developed that can cross the bloodbrain barrier giving us additional tools to treat BMs. The guidelines presented here focus on the efficacy of new targeted systemic therapies and immunotherapies on CNS BMs from breast, melanoma, and lung cancers.
Key words
Full text:
1
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Brain Neoplasms
/
Central Nervous System
/
Central Nervous System Neoplasms
/
Cerebrum
/
Melanoma
Language:
En
Journal:
Clin. transl. oncol. (Print)
Year:
2022
Document type:
Article